Arvinas reports Q1 EPS (90c), consensus (63c)

Reports Q1 revenue $15.6M, consensus $34.84M. “The approval of VEPPANU is a defining achievement for Arvinas (ARVN) and reflects the culmination of more than a decade of focused work to translate our PROTAC science into our first approved therapy,” said Randy Teel, President and Chief Executive Officer at Arvinas. “I’m proud to lead an organization advancing an industry-leading portfolio of degraders – one that has now joined the short list of those able to bring a new therapeutic modality from discovery to approval. As we move through the remainder of the year, our focus is on delivering key data and clinical milestones that we believe will further validate our approach and clearly distinguish our programs in an increasingly competitive environment.”